For decades, the placebo effect — the phenomenon where ... Then a 2010 study revealed significant effects of open-label placebos for irritable bowel syndrome (IBS). The researchers in the ...

A recent study published in the British Medical Journal has shown that even when patients know they're taking a placebo, the ...

Microdosing might not work the way we think—but that doesn’t mean it doesn’t work. Here’s what science and the placebo effect ...

Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

Immunic will continue developing its multiple sclerosis (MS) drug, vidofludimus calcium (IMU-838), despite a Phase II trial ...

Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

Phase 2 data featured in an oral presentation at the American Academy of Neurology Annual Meeting ATH434-202 open-label trial in advanced MSA completed in March 2025 Cash balance on 31 March 2025 of ...

In a first-of-its-kind human trial, researchers transplanted iPS-cell-derived dopaminergic progenitors into patients with ...